NCT02758587 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Status UNKNOWN Phase PHASE1/PHASE2
NCT02748798 Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders Status TERMINATED Phase EARLY_PHASE1
NCT02716272 Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients Status COMPLETED Phase PHASE2
NCT02709512 Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Status COMPLETED Phase PHASE2/PHASE3
NCT02661100 A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Status WITHDRAWN Phase PHASE1/PHASE2
NCT02648763 Staging Procedures to Diagnose Malignant Pleural Mesothelioma Status TERMINATED Phase N/A
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02613312 Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma Status TERMINATED Phase N/A
NCT02613299 Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma Status TERMINATED Phase N/A
NCT02611037 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Status COMPLETED Phase PHASE2
NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT02610140 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) Status COMPLETED Phase PHASE2
NCT02592551 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Status COMPLETED Phase PHASE2
NCT02511600 Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication Status WITHDRAWN Phase PHASE3
NCT02414269 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02395679 Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients Status UNKNOWN Phase PHASE1